Pharma feed

N
Novartis AG
PM Live· 24 May 2019

Novartis sees five new $1bn-plus launches in next two years

Novartis is entering one of its most productive R&D periods, with 25 potential blockbusters in the pipeline, including five new molecules which reach the market in the next two years. That was the message delivered by CEO Vas Narasimhan at the company’s annual R&D update, as Novartis showcased a pipeline with more than 200 projects in clinical development, and 60 major submissions planned in before the end of 2021.

  • Novartis AG
  • New Offerings
  • News Articles
  • News and Other Websites
N
AbbVie Inc
FirstWord Pharma· 24 May 2019

AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA, a treatment for chronic lymphocytic leukemia (CLL)

Following the signing of an agreement between AbbVie and the pan-Canadian Pharmaceutical Alliance (pCPA), Ontario is the first province to reimburse VENCLEXTA. VENCLEXTA is the first and only BCL-2 inhibitor to be approved in Canada.

  • AbbVie Inc
  • Partnerships and Alliances
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Industry Reports· 24 May 2019

Pet Medication Market 2019 Precise Outlook – Zoetis, Merck, Elanco, Bayer, Boehringer, Novartis – Industry Reports

2019-2025 Global Pet Medication Market Research Report: The report presents an in-depth assessment of the Pet Medication including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies.

  • Merck & Co., Inc.
  • Novartis AG
  • New Offerings
  • News Articles
  • News and Other Websites
N
Eli Lilly and Co
Pharmaceutical Technology· 24 May 2019

Lilly starts selling half-price version of Humalog insulin

Eli Lilly has announced the market launch of a half-price, generic version of its Humalog insulin. Called Insulin Lispro Injection, the product is available in a vial or within a KwikPen. Insulin Lispro can be substituted for Humalog as they contain the same insulin.

  • Eli Lilly and Co
  • New Offerings
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Honest Version· 24 May 2019

Psoriasis Drug Market 2019 to Witness Huge Growth by 2025 with Top Key Players- AbbVie, Johnson & Johnson, Bayer, Galderma and more… – Honest Version

A new market study, titled “Global Psoriasis Drug Market Insights, Forecast to 2025”, has been featured on WiseGuyReports. Psoriasis Drug Market Psoriasis is a long-lasting autoimmune disease which is characterized by patches of abnormal skin. The global Psoriasis Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.

  • Johnson & Johnson
  • Galderma S.A.
  • New Offerings
  • News Articles
  • News and Other Websites
Regeneron Pharmaceuticals Inc
Regeneron· 24 May 2019

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y., May 23, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Goldman Sachs 40th Annual Global Healthcare Conference at 9:20 a.m. Pacific Time ( 12:20 p.m. Eastern Time ) on Tuesday, June 11, 2019 .

  • Regeneron Pharmaceuticals Inc
  • Regeneron
  • Events
  • Press Releases
  • Company Websites
N
GlaxoSmithKline PLC
FirstWord Pharma· 24 May 2019

China approves GlaxoSmithKline's shingles vaccine Shingrix

GlaxoSmithKline announced Thursday that China's National Medical Products Administration has approved Shingrix following an expedited review for the prevention of shingles in adults aged 50 years or older.

  • GlaxoSmithKline PLC
  • Medical Corp
  • New Offerings
  • News Articles
  • News and Other Websites
Informa PLC
Informa· 24 May 2019

Novartis' New Oncology CEO Schaffert Has A Potential Blockbuster Launch On Her Hands

All fields are required. Please make sure all fields are completed.

  • Informa PLC
  • Novartis AG
  • Management Changes
  • Company Websites
N
Merck & Co., Inc.
FirstWord Pharma· 24 May 2019

Friday Five - The pharma week in review (23 May 2019)

Merck & Co. acquires Peloton Merck & Co. swooped in to acquire Peloton Therapeutics this week, heading off a planned IPO by the biotech company. The upfront cost is $1 billion. The deal provides Merck access to PT2977, an oral therapy with a novel mechanism of action currently moving into late-stage development for renal cancer.

  • Peloton Therapeutics Inc
  • Merck & Co., Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Colgate-Palmolive (India) Limited
Law 360· 24 May 2019

J&J, Colgate Duck Sanctions After Expert Blows Past Order

Law360, Oakland, Calif. (May 23, 2019, 8:18 PM EDT) -- A California judge on Thursday admonished a microbiologist testifying for Johnson & Johnson and Colgate-Palmolive in a jury trial over claims their talcum powder products contained cancer-causing asbestos, saying she “clearly violated” his pretrial rulings by raising an off-limits topic, but declined to sanction the companies.

  • Colgate-Palmolive (India) Limited
  • Johnson & Johnson
  • Colgate-Palmolive Company
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
CTC Ltd
Enherald· 24 May 2019

Advisors Preferred Trimmed Holding in Pfizer (PFE) as Stock Declined; Ctc Stake in Facebook (FB) Has Raised by $17.37 Million as Market Valuation Rose

Advisors Preferred Llc decreased its stake in Pfizer Inc (PFE) by 51.33% based on its latest 2018Q4 regulatory filing with the SEC. Advisors Preferred Llc sold 8,240 shares as the company’s stock declined 4.08% while stock markets rallied.

  • CTC Ltd
  • Pfizer Inc.
  • Funding Activities
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Nbonews· 24 May 2019

Merck & Co (MRK) Holder Icon Advisers Trimmed Position by $426,512; Snyder Capital Management LP Maintains Position in Coherent (COHR)

Snyder Capital Management LP increased its stake in Coherent Inc. (COHR) by 8.38% based on its latest 2018Q4 regulatory filing with the SEC. Snyder Capital Management LP bought 8,557 shares as the company’s stock rose 1.83% with the market.

  • Merck & Co., Inc.
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Celgene Corp
Seeking Alpha· 24 May 2019

My Top Merger-Arb Pick: Celgene

Recently for those that trade M&A stocks it has been a case of arbageddon. So many current deals have hit potholes in one way or another. Spark Therapeutics (ONCE) has filed and then refiled their respective pre-merger notification and report forms to federal regulators an unusually high three times.

  • Celgene Corp
  • M&A Activities
  • News Articles
  • News and Other Websites
Novartis AG
Bit (ly)· 24 May 2019

Novartis chief Vas Narasimhan wants you to know about the ’25-plus’ blockbusters he has in the pipeline

Vas Narasimhan has been CEO at Novartis for just a little more than a year since his promotion from development chief. And in today’s investor meeting, after spinning off Alcon and putting the wheels in motion to do a makeover at the suffering generics wing Sandoz, the spotlight is being turned straight at his prized possession: the pipeline.

  • Alcon Inc
  • Novartis AG
  • Bitly Inc
  • Management Changes
  • Company Websites
N
Pfizer Inc.
Life Sciences IP Review· 24 May 2019

Alphabet's Verily in digital research alliance with Pfizer and others

Piotr Swat / Shutterstock.com Verily, which is a subsidiary of Google’s parent company Alphabet, yesterday announced that it had partnered with Novartis, Otsuka, Pfizer, and Sanofi in efforts to develop digitally-innovative clinical research programmes. Alphabet’s Verily, which was launched in 2015, uses health data to create interventions that prevent and manage diseases.

  • Pfizer Inc.
  • Sanofi
  • Partnerships and Alliances
  • New Offerings
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
FirstWord Pharma· 24 May 2019

Friday Five - The pharma week in review (23 May 2019)

Merck & Co. acquires Peloton Merck & Co. swooped in to acquire Peloton Therapeutics this week, heading off a planned IPO by the biotech company. The upfront cost is $1 billion. The deal provides Merck access to PT2977, an oral therapy with a novel mechanism of action currently moving into late-stage development for renal cancer.

  • Peloton Therapeutics Inc
  • Merck & Co., Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Sanofi
The Pharma Letter· 24 May 2019

Cegedim partners with Sanofi on RWE for healthcare in Europe

To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.

  • CEGEDIM GROUP
  • Sanofi
  • RWE Group
  • Partnerships and Alliances
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Connectivity Market· 24 May 2019

Global Metabolite Chemistry Reagents Market Statistics and Trends 2019-2024 : BioVision, Merck, Thermo Fisher Scientific, BD, Abbott

The Global Metabolite Chemistry Reagents Market report includes a scrupulous analysis of the Metabolite Chemistry Reagents market in the forecasted period. It also assesses the Metabolite Chemistry Reagents market in terms of topography, technology, and consumers.

  • Merck & Co., Inc.
  • Thermo Fisher Scientific Inc.
  • BIOVISION
  • New Offerings
  • News Articles
  • News and Other Websites
N
Cipla Ltd
Themarketresearchnews· 24 May 2019

Finasteride Market Production Status, Growth and Demands 2019: Merck, Actavis, Sandoz, Teva Pharmaceuticals, Cipla, RelonChem – The Market Research News

Finasteride is a prescription drug in tablet form. Finasteride Market Report by Material, Application, and Geography – Global Forecast to 2024 is a professional and in-depth research report on the world’s major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).

  • Cipla Ltd
  • Sandoz Inc
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd
  • New Offerings
  • News Articles
  • News and Other Websites
N
Paradigm Ltd
Sundance Herald· 24 May 2019

Paradigm Financial Partners LLC Takes $2.01 Million Position in Merck & Co., Inc. (MRK)

Paradigm Financial Partners LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 26,328 shares of the company’s stock, valued at approximately $2,012,000.

  • Paradigm Ltd
  • Merck & Co., Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Wal-Mart Stores, Inc.
Mole Post Gazette· 24 May 2019

External Nasal Dilator Market 2019 Global Growing Trend – GSK, Equate (Walmart), ASO Medical, Hongze Sanitary, SK&F – Mole Post Gazette

As per a new research report titled Global External Nasal Dilator Market Professional Survey Report 2019, the forenamed market delivers extensive analysis of market trends and shares. It’s an insightful data for all the players operating in the market.

  • Wal-Mart Stores, Inc.
  • SK Group
  • GlaxoSmithKline PLC
  • Medical Corp
  • New Offerings
  • News Articles
  • News and Other Websites
N
Novartis AG
Global Genes· 24 May 2019

FDA Approves Gene Therapy Zolgensma for SMA; Novartis Sets Price at $2.1 Million

The U.S. Food and Drug Administration approved AveXis’ Zolgensma, the first gene therapy to treat children less than two years of age with the most severe form of spinal muscular atrophy, and a leading genetic cause of infant death.

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Trentdailytimes· 24 May 2019

New Mexico Educational Retirement Board Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

New Mexico Educational Retirement Board reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 228,343 shares of the company’s stock after selling 10,800 shares during the quarter.

  • Johnson & Johnson
  • Management Changes
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Sundance Herald· 24 May 2019

Merck 1Q net quadruples vaccine Revenue soar

Surging sales of the cancer immunotherapy medication and vaccines Keytruda led during the quarter to a quadrupling of profit at Merck because it blew past Wall Street expectations. Sales of Keytruda jumped 55% to $2.27 billion, about one-quarter of overall revenue.

  • Merck & Co., Inc.
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Bristol-Myers Squibb Co
Sundance Herald· 24 May 2019

Bristol-Myers Squibb Co (NYSE:BMY) Position Boosted by Tiaa Fsb

TIAA FSB grew its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 122,050 shares of the biopharmaceutical company’s stock after acquiring an additional 3,134 shares during the quarter.

  • Bristol-Myers Squibb Co
  • FSB Tech
  • M&A Activities
  • News Articles
  • News and Other Websites
1 2 3 4 5